Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Protein matrix vaccine compositions including polycations

A protein matrix and polycation technology, applied in the field of protein matrix vaccines and vaccine administration, can solve problems such as complexity, production difficulties, and prevention of distribution

Active Publication Date: 2014-04-23
MATRIVAX
View PDF7 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] However, despite the promising immunity of conjugate vaccines, they are extremely difficult and complex (and expensive) to produce, which greatly prevents their distribution worldwide where vaccination is required

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Protein matrix vaccine compositions including polycations
  • Protein matrix vaccine compositions including polycations
  • Protein matrix vaccine compositions including polycations

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0171] Example 1: Vi-CRM197-αPLL PCMV

[0172] Use from Salmonella enterica serotype Typhi as antigen, use avirulent diphtheria toxin CRM197 as carrier protein (made in Matrivax Research and Development Corporation, Boston, MA, USA), and α-poly-L-lysine (Sigma- Aldrich, St. Louis, MO) as the polycation, investigated the effect of adding polycations to matrix vaccine compositions.

[0173] Vi is a highly anionic homopolymer composed of O-acetylated (α1-4)-D-GalANAc variable at C-3. One of the currently approved vaccines for typhoid fever is (Sanofi Pasteur SA) containing non-conjugated Vi polysaccharide as antigen. In the initial study, to test whether a protein matrix vaccine could be successfully used to deliver Vi antigen and elicit an immune response, PCMV was prepared in a reaction containing 4 mg / mL Vi as the antigen and 4 mg / mL CRM197 as the matrix-forming carrier protein . Matrix formation was initiated by adding glutaraldehyde as a crosslinker. After incubation...

Embodiment 2

[0184] Example 2: Improved isolation of Vi-CRM197-αPLL PCMV

[0185] For better removal of low molecular weight species (presumably unentrapped, unconjugated antigen aggregates) from PCMV particles, a longer (90 cm) size exclusion column was used. Specifically, a PCMV crosslinking reaction mixture containing 4 mg / ml Vi, 4 mg / ml CRM197 and 0.01% α-poly-L-lysine (150-300 KDa) was prepared. Vi and αPLL were incubated for 15 min at room temperature with constant shaking before adding 0.25% glutaraldehyde and CRM197. Incubation was continued for an additional 10 minutes at room temperature with constant shaking, followed by 24 hours at 4°C with constant shaking. After separation of reaction products on SEC columns, protein and polysaccharide levels were determined by microBCA and stains-all assays, respectively. To determine whether the size or molecular weight of PCMV particles could affect its immunogenicity, fractions from 3 different elution points from the SEC column were ...

Embodiment 3

[0191] Example 3: PPS18C-CRM197-αPLL PCMV

[0192] In the case of improved Vi entrapment using α-PLL, we next tested whether α-PLL would improve entrapment of the less negatively charged pneumococcal polysaccharide PPS18C. Unlike Vi, where every sugar residue is negatively charged, PPS18C has only one negative charge for every five sugar residues. However, inclusion of 0.04% α-PLL (15–30 kDa) in the PCMV reaction resulted in a 35% shift of the polysaccharide from the lower molecular weight to the higher molecular weight fraction upon SEC separation ( Figure 4 ). Most of the CRM197 present in the PCMV reactions also co-localized with the high molecular weight fraction. It was shown by using a capture ELISA assay that the polysaccharides present in the high molecular weight fraction were all captured in the PCMV particles, which were bound to the ELISA plate by an anti-CRM197 antibody, and the polysaccharides were detected using serotype-specific antisera (data not shown )...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to immunogenic compositions containing one or more antigens of interest, one or more carrier proteins, and one or more polycations, wherein the antigen of interest is entrapped with cross-linked carrier protein matrix and one or more polycations, methods of making such vaccines, and methods of vaccine administration.

Description

[0001] Cross-references to related applications [0002] This application claims priority to US Provisional Application No. 61 / 487,663, filed May 18, 2011, the contents of which are hereby incorporated by reference in their entirety. field of invention [0003] The present invention relates to immunogenic compositions, methods of preparing vaccines, and methods of administering vaccines. In particular, the present invention relates to protein matrix vaccines featuring a protein of interest entrapped in a cross-linked carrier protein matrix wherein poly-L-lysine or other polycations are used to form the antigen-entrapped protein matrix . Background of the invention [0004] Vaccination against bacterial infections is an important medical pursuit that represents a preventive medical intervention recommended for almost every individual. The design of vaccines against bacterial infections or the pathogenesis of bacterial infections often targets bacterial proteins, such as tox...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/00A61K39/38
CPCA61K39/07A61K2039/6037A61K39/116A61K39/0275A61K2039/55555A61K39/092A61K45/06A61K39/39A61K39/385A61K2039/55505A61K2039/55516A61K2039/6068A61K2039/6093A61K2039/70A61P31/04A61P37/04Y02A50/30A61K47/36A61K47/42A61K47/30
Inventor K·P·基利恩R·T·卡尔蒂
Owner MATRIVAX
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com